IHH's unit. The error also appeared in an earlier version of the story.)(Reuters) - IHH Healthcare said on Thursday its ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

The mathematics were still causing a few heads to be scratched after Arsenal's 3-0 victory over Dinamo Zagreb on Wednesday, but Declan Rice gave the new Champions League format a thumbs up.

The FDA on Friday approved AstraZeneca and Daiichi ... can live up to that forecast, or whether the setbacks experienced in 2024 were early signs of a bleaker future for the drug. Dale Shuster, head ...

DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and AstraZeneca. DATROWAY is the ...

Elon Musk was seen giving thumbs-up during Donald Trump's inaugural speech, where he vowed to put the American flag on Mars. New strain in Calif. Get the USA TODAY app Start the day smarter ☀️ ...

Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39 ...

(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab deruxtecan) has been approved in the United States for ...

Trump went on to say American astronauts would "plant the stars and stripes on the planet Mars," which drew an enthusiastic thumbs-up from SpaceX CEO Elon Musk.Jan. 20, 2025 ...

Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a milestone in the company’s efforts to turn it into a widely used blockbuster.

A targeted cancer therapy from AstraZeneca’s alliance with Daiichi Sankyo is now FDA approved to ... But Datroway’s results come up short compared with Enhertu. The Citeline report also ...

The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan or Dato-DXd) for adult patients with previously treated, unresectable, or metastatic HR-positive, HER2-negative ...